Ensign Peak Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Ensign Peak Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88,341	Closed	-$516K	–	1803
2022 Q4	$516K	Hold	88,341	–	–	﹤0.01%	1611
2022 Q3	$592K	Hold	88,341	–	–	﹤0.01%	1366
2022 Q2	$372K	Buy	+88,341	New	+$350K	﹤0.01%	1583
2021 Q1	–	Sell	-38,970	Closed	-$493K	–	1898
2020 Q4	$493K	Buy	+38,970	New	+$444K	﹤0.01%	1608

Ensign Peak Advisors's CNCE Position: Q1 2023 in Review

Ensign Peak Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 88,341 shares — an estimated $516K sold.

Ensign Peak Advisors first reported a position in CNCE in Q4 2020 and held it in 4 quarters. The position peaked at $592K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Ensign Peak Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Ensign Peak Advisors sold 88,341 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $516K.
Ensign Peak Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
Ensign Peak Advisors's Concert Pharmaceuticals, Inc. position peaked at $592K in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Ensign Peak Advisors's 13F filing for Q1 2023, filed 15 May 2023.